Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
2021 · Cancer Cell · 886 citations
https://doi.org/10.1016/j.ccell.2020.12.014
S
Simon Heeke
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
158
Papers
4.0K
Citations
28
h-index
55
i10-index
Simon Heeke is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Lung Cancer Research Studies. The author has an h-index of 28, co-authored 135 publications.
ORCID: 0000-0002-5916-534XPapers by this author
worksStructure-based classification predicts drug response in EGFR-mutant NSCLC
2021 · Nature · 427 citations
https://doi.org/10.1038/s41586-021-03898-1
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
2024 · Cancer Cell · 98 citations
https://doi.org/10.1016/j.ccell.2024.01.001
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve <i>EGFR</i> -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
2024 · Journal of Clinical Oncology · 35 citations
https://doi.org/10.1200/jco.24.00533
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
2024 · npj Precision Oncology · 32 citations
https://doi.org/10.1038/s41698-024-00720-9
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies
2023 · Journal of Thoracic Oncology · 17 citations
https://doi.org/10.1016/j.jtho.2023.08.034
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat